Viridian Therapeutics Statistics

Total Valuation

Viridian Therapeutics has a market cap or net worth of GBP 1.18 billion. The enterprise value is 740.88 million.

Market Cap	1.18B
Enterprise Value	740.88M

Important Dates

The next estimated earnings date is Thursday, February 27, 2025.

Earnings Date	Feb 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+42.07%
Shares Change (QoQ)	+4.02%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	79.15M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	3.05
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.86
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.03

Financial Position

The company has a current ratio of 18.55, with a Debt / Equity ratio of 0.03.

Current Ratio	18.55
Quick Ratio	18.21
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.12
Interest Coverage	-103.04

Financial Efficiency

Return on equity (ROE) is -51.88% and return on invested capital (ROIC) is -34.14%.

Return on Equity (ROE)	-51.88%
Return on Assets (ROA)	-32.14%
Return on Capital (ROIC)	-34.14%
Revenue Per Employee	2,397
Profits Per Employee	-2.04M
Employee Count	94
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.23% in the last 52 weeks. The beta is 1.11, so Viridian Therapeutics's price volatility has been higher than the market average.

Beta (5Y)	1.11
52-Week Price Change	-7.23%
50-Day Moving Average	20.30
200-Day Moving Average	17.46
Relative Strength Index (RSI)	48.46
Average Volume (20 Days)	1,058

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.78

Income Statement

In the last 12 months, Viridian Therapeutics had revenue of GBP 225,322 and -191.81 million in losses. Loss per share was -3.18.

Revenue	225,322
Gross Profit	-118.98M
Operating Income	-211.18M
Pretax Income	-191.81M
Net Income	-191.81M
EBITDA	-210.75M
EBIT	-211.18M
Loss Per Share	-3.18

Full Income Statement

Balance Sheet

The company has 561.99 million in cash and 17.36 million in debt, giving a net cash position of 544.63 million.

Cash & Cash Equivalents	561.99M
Total Debt	17.36M
Net Cash	544.63M
Net Cash Per Share	n/a
Equity (Book Value)	527.86M
Book Value Per Share	4.89
Working Capital	541.66M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -146.97 million and capital expenditures -332,015, giving a free cash flow of -147.30 million.

Operating Cash Flow	-146.97M
Capital Expenditures	-332,015
Free Cash Flow	-147.30M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-93,722.27%
Pretax Margin	-85,127.23%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Viridian Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-42.07%
Shareholder Yield	-42.07%
Earnings Yield	-16.25%
FCF Yield	-12.48%

Stock Splits

The last stock split was on November 13, 2020. It was a reverse split with a ratio of 0.0666666667.

Last Split Date	Nov 13, 2020
Split Type	Reverse
Split Ratio	0.0666666667

Scores

Viridian Therapeutics has an Altman Z-Score of 7.36.

Altman Z-Score	7.36
Piotroski F-Score	n/a